Phase II Study Of Lenalidomide and Rituximab in Patients With treatment naive and relapsed Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2018
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Results assessing efficacy of lenalidomide and rituximab combination in chronic lymphocytic patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results (n= 129) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 13 Aug 2014 New trial record